新城疫病毒样颗粒研究进展

doi:10.11843/j.issn.0366-6964.2014.05.002

摘要/Abstract

摘要：

病毒样颗粒（virus-like particles，VLPs）是指利用异源宿主系统表达的病毒结构蛋白自行组装成不含病毒基因组、不能复制、不具有感染能力的病毒样蛋白颗粒。VLPs具备构想逼真、安全、稳定、可刺激体液和细胞免疫应答、作为载体表达其他抗原以及可设计成区分自然感染与免疫接种等诸多优点。这些优点使得VLPs在过去30年中成为新一代疫苗制备平台。作者就新城疫VLPs相关研究进展进行较为详尽的综述，以期为中国新城疫VLPs的研究提供参考。

Abstract:

Virus-like particles (VLPs) refers to the virus structural protein self assembling into particles without virus gneome by using heterologous host system.It can’t copy and does not have the infection ability.VLPs combine many of the advantages，such as，well-defined geometry，safety，high stability，inducing strong humoral and cellular immune responses，applicability as vectors for the presentation of foreign antigens and amenable to fulfil the Differentiating Infected from Vaccinated Animals (DIVA).On behalf of above advantages，over the last three decades，VLPs have evolved to become a widely accepted new technology in the field of vaccinology.Here，in order to provide reference to the research of Newcastle disease VLPs，we review the current status of Newcastle disease VLPs to provid a guidelines for us to study the Newcastle disease VLPs in the future.

中图分类号:

S852.659.5

戈胜强,赵明,吴晓东,王静静,刘华雷,包静月,王志亮. 新城疫病毒样颗粒研究进展[J]. 畜牧兽医学报, 2014, 45(5): 686-691.

GE Sheng-qiang， ZHAO Ming，WU Xiao-dong，WANG Jing-jing，LIU Hua-lei，BAO Jing-yue，WANG Zhi-liang. Progress of Newcastle Disease Virus-like Particles[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2014, 45(5): 686-691.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.xmsyxb.com/CN/10.11843/j.issn.0366-6964.2014.05.002

https://www.xmsyxb.com/CN/Y2014/V45/I5/686

参考文献

［1］PANDEY A，SINGH N，SAMBHARA S,et al.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses［J］.Hum Vaccin，2010，6(2):178-188.
［2］ZHOU S，LIU R，ZHAO X，et al.Viral proteomics：the emerging cutting-edge of virus research［J］. Sci China Life Sci，2011，54(6):502-512.
［3］FREUNDLICH M M.Origin of the Electron Microscope［J］.Science，1963，142(3589):185-188.
［4］PORTER K R，THOMPSON H P.A particulate body associated with epithelial cells cultured from mammary carcinomas of mice of a milk-factor strain［J］.J Eep Med，1948，88(1):15-24.
［5］戈胜强，王志亮.禽流感病毒样颗粒研究进展［J］.病毒学报，2013，29(2):224-232.
［6］KENDAL A P，GALPHIN J C，PALMER E L.Replication of influenza virus at elevated temperatures：production of virus-like particles with reduced matrix protein content［J］.Virology，1977，76(1):186-195.
［7］NEUMANN H，SCHWASS V，ECKERSKORN C，et al.Identification and characterization of the genes encoding three structural proteins of the Thermoproteus tenax virus TTV1［J］.Mol Gen Genet，1989，217(1):105-110.
［8］BURRELL C J，MACKAY P，GREENAWAY P J，et al.Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322［J］.Nature，1979，279(5708):43-47.
［9］COHEN B J，RICHMOND J E.Electron microscopy of hepatitis B core antigen synthesized in E.coli［J］.Nature，1982，296(5858):677-679.
［10］SMITH G E，SUMMERS M D，FRASER M J.Production of human beta interferon in insect cells infected with a baculovirus expression vector［J］.Mol Cell Biol，1983，3(12):2156-2165.
［11］ZELTINS A.Construction and characterization of virus-like particles：a review［J］.Mol Biotechnol，2013，53(1):92-107.
［12］ROY P.Genetically engineered particulate virus-like structures and their use as vaccine delivery systems［J］.Intervirology，1996，39(1-2):62-71.
［13］GÓMEZ-PUERTAS P，ALBO C，PÉREZ-PASTRANA E，et al.Influenza virus matrix protein is the major driving force in virus budding［J］.J Virol，2000，74(24):11538-11547.
［14］LI T C，ZHANG J，SHINZAWA H，et al.Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus［J］.J Med Virol，2000，62(3):327-333.
［15］COURSAGET P.Serology for human papillomavirus［J］.Salud Publica Mex，2003，45(Sup3):S361-366.
［16］TAKAMURA S，NIIKURA M，LI T C，et al.DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration［J］.Gene Ther，2004，11(7):628-635.
［17］CHACKERIAN B.Virus-like particles：flexible platforms for vaccine development［J］.Expert Rev Vaccines，2007，6(3):381-390.
［18］JENNINGS G T，BACHMANN M F.The coming of age of virus-like particle vaccines［J］.Biol Chem，2008，389(5):521-536.
［19］ROY P，NOAD R.Virus-like particles as a vaccine delivery system：myths and facts［J］.Hum Vaccin，2008，4(1):5-12.
［20］PLUMMER E M，MANCHESTER M.Viral nanoparticles and virus-like particles：platforms for contemporary vaccine design［J］.Wires Nanomed Nanobi，2010，3(2):174-196.
［21］ROLDÃO A，MELLADO M C，CASTILHO L R，et al.Virus-like particles in vaccine development［J］.Expert Rev Vaccin，2010，9(10):1149-1176.
［22］MICHEL M L，TIOLLAIS P.Hepatitis B vaccines：protective efficacy and therapeutic potential［J］.Pathol Biol (Paris)，2010，58(4):288-295.
［23］NOAD R，ROY P.Virus-like particles as immunogens［J］.Trends Microbiol，2003，11(9):438-444.
［24］FAUSCH S C，DA SILVA D M，EIBEN G L，et al.HPV protein/peptide vaccines：from animal models to clinical trials［J］. Front Biosci，2003，8:s81-91.
［25］STANLEY M A.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection［J］.Expert Rev Vaccin，2003，2(3):381-389.
［26］HARPER D M，FRANCO E L，WHEELER C，et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women：a randomised controlled trial［J］. Lancet，2004，364(9447):1757-1765.
［27］KEIM B.Controversy over cervical cancer vaccine spurs safety surveillance［J］.Nat Med，2007，13(4):392-393.
［28］CORONEL E C，MURTI K G，TAKIMOTO T，et al.Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures［J］.J Virol，1999，73(8):7035-7038.
［29］CIANCANELLI M J，BASLER C F.Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization［J］.J Virol，2006，80(24):12070-12078.
［30］PATCH J R，CRAMERI G，WANG L F，et al.Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein［J］.Virol J，2007，4:1.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781425/pdf/1743-422X-4-1.pdf.
［31］TAKIMOTO T，MURTI K G，BOUSSE T，et al.Role of matrix and fusion proteins in budding of Sendai virus［J］. J Virol，2001，75(23):11384-11391.
［32］SCHMITT A P，LESER G P，WANING D L，et al.Requirements for budding of paramyxovirus simian virus 5 virus-like particles［J］.J Virol，2002，76(8):3952-3964.
［33］LIU F，WU X，LI L，et al.Use of baculovirus expression system for generation of virus-like particles：successes and challenges［J］.Protein Expr Purif，2013，90(2)：104-116.
［34］KANG S M，SONG J M，QUAN F S，et al.Influenza vaccines based on virus-like particles［J］.Virus Res，2009，143(2):140-146.
［35］WANG X J，GU K，XIONG Q Y，et al.A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK［J］.Vaccine，2009，27(52):7377-7384.
［36］JIANG Z，TONG G，CAI B，et al.Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris［J］.Protein Expr Purif，2011，80(2):203-210.
［37］MORRISON T G，PANTUA H D.Virus-like particles as vaccines for paramyxovirus：USA，WO2007019247 A2 ［P］.
［38］MAHMOOD K，SMITH G，PUSHKO P.Chimeric Newcastledisease virus VLPs：USA，WO 2008103819 A2 ［P］.
［39］PANTUA H D，MCGINNES L W，PEEPLES M E，et al.Requirements for the assembly and release of Newcastle disease virus-like particles［J］.J Virol，2006，80(22):11062-11073.
［40］MCGINNES L W，PANTUA H，LALIBERTE J P，et al.Assembly and biological and immunological properties of Newcastle disease virus-like particles［J］.J Virol，2010，84(9):4513-4523.
［41］冷勇，宋振辉，卿家超，等.猪传染性胃肠炎病毒M、sM基因重组杆状病毒的构建及病毒样颗粒的组装［J］.畜牧兽医学报，2013，44（9）：1432-1437.
［42］闻晓波.新城疫病毒样颗粒的构建及其出芽机制的研究［D］.北京：中国农业科学院，2006.
［43］吴芬芳，闫丽辉，曹殿军，等.新城疫病毒样颗粒(ND—VLPs)免疫效力的研究［J］.中国预防兽医学报，2008，30(1):42-46，63.
［44］MURAWSKI M R，MCGINNES L W，FINBERG R W，et al.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice，with no evidence of immunopathology［J］.J Virol，2010，84(2):1110-1123.
［45］MCGINNES L W，GRAVEL K A，FINBERG R W，et al.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins［J］.J Virol，2011，85(1):366-377.
［46］SHEN H，XUE C，LV L，et al.Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease［J］.Virus Res，2013，178(2):430-436.
［47］NAGY E，HUBER P，KRELL P J，et al.Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV［J］.J Gen Virol，1991，72(Pt3):753-756.
［48］ONG H K，ALI A M，OMAR A R，et al.Cloning and expression of the HN， gene from the velogenic viscerotropic Newcastle disease virus strain AF2240 in Sf9 insect cells［J］.Cytotechnology，2000，32(3):243-251.
［49］李太元，金宁一，丁壮，等.新城疫病毒F₄₈E₈株HN基因在杆状病毒系统中表达［J］.中国生物制品学杂志，2002，15(6):334-336.
［50］SEAL B S，KING D J，SELLERS H S.The avian response to Newcastle disease virus［J］.Dev Comp Immunol，2000，24(2-3):257-268.
［51］TAKIMOTO T，PORTNER A.Molecular mechanism of paramyxovirus budding［J］.Virus Res，2004，106(2):133-145.
［52］SANDERSON C M，WU H H，NAYAK D P.Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo［J］.J Virol，1994，68(1):69-76.
［53］ALI A，NAYAK D P.Assembly of Sendai virus：M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein［J］.Virology，2000，276(2):289-303.
［54］MORRISON T G.Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens［J］.Future Virol，2010，5(5):545-554.
［55］BRIGHT R A，CARTER D M，CREVAR C J，et al.Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle［J］.PLoS One，2008，3(1)：e1501.

[1]	孟令宅, 陈春丽, 于蒙蒙, 王占新, 王素艳, 刘鹏, 何塔娜, 郭茹, 陈运通, 刘长军, 祁小乐, 吴志强, 高玉龙. B亚型禽偏肺病毒对黄羽肉鸡致病性分析及其灭活疫苗免疫效果评价[J]. 畜牧兽医学报, 2023, 54(12): 5154-5161.
[2]	蒋盛强, 胡靖, 陈红英. H1N1亚型流感病毒感染A549细胞的环状RNA表达分析[J]. 畜牧兽医学报, 2023, 54(11): 4724-4734.
[3]	张傲, 谭斌, 刘可欣, 刘佳利, 张淑琴. 一株H1N1亚型猪流感病毒全基因组特征分析[J]. 畜牧兽医学报, 2023, 54(11): 4866-4871.
[4]	何辰香, 高闪电, 田占成, 独军政, 王锦明, 关贵全, 殷宏. 基于G_NS蛋白的牛流行热病毒感染与免疫鉴别诊断ELISA方法的建立[J]. 畜牧兽医学报, 2023, 54(10): 4320-4326.
[5]	常益铭, 汤承, 岳华. 牦牛源牛呼吸道合胞体病毒的分子流行病学调查[J]. 畜牧兽医学报, 2023, 54(5): 2030-2041.
[6]	方源, 侯巧弟, 项超辉, 赵红奕, 齐雪峰. IFITM3对小反刍兽疫病毒在山羊子宫内膜上皮细胞中增殖的调控效应[J]. 畜牧兽医学报, 2023, 54(5): 2200-2207.
[7]	李舜, 李桂珍, 原耀贤, 李康健, 马春全, 李守军, 黄良宗, 马骏. PA-X基因的长度变化对H3N2犬流感病毒复制能力和致病性的影响[J]. 畜牧兽医学报, 2023, 54(1): 272-280.
[8]	崔明仙, 王星博, 黄彦铭, 卞希一, 冯梦珂, 颜焰, 董伟仁, 周继勇. 3株H3N2亚型禽流感病毒的基因组特征与演化分析[J]. 畜牧兽医学报, 2022, 53(11): 4116-4122.
[9]	于蒙蒙, 包媛玲, 王素艳, 辛子琪, 刘鹏, 冯笑艳, 孟令宅, 郭茹, 张艳萍, 刘长军, 祁小乐, 李俊平, 王笑梅, 高玉龙. B亚型禽偏肺病毒的分离鉴定及致病性研究[J]. 畜牧兽医学报, 2022, 53(10): 3540-3549.
[10]	周勇, 李知新, 鲁宏伟, 孙燕, 李甜, 杜凡姝, 蒲娟. 我国H5和H7N9亚型高致病性禽流感的监测及疫情暴发分析[J]. 畜牧兽医学报, 2022, 53(9): 3093-3106.
[11]	潘春容, 邓瑞雪, 胡林杰, 朱学亮, 孙跃峰, 王桂荣, 蒙学莲. 组蛋白去乙酰化酶抑制剂对小反刍兽疫病毒复制的影响[J]. 畜牧兽医学报, 2022, 53(7): 2307-2316.
[12]	陈子轩, 张楠, 胡群, 全柯吉, 秦涛, 陈素娟, 彭大新, 刘秀梵. 我国H9N2亚型禽流感病毒血凝素蛋白145和153位抗原位点变异分析[J]. 畜牧兽医学报, 2022, 53(4): 1165-1172.
[13]	段志强, 谢玲玲, 陈佳琪, 唐宏, 王燕碧, 赵采芹, 赵佳福. 新城疫病毒M蛋白与宿主蛋白相互作用的研究进展[J]. 畜牧兽医学报, 2022, 53(1): 32-42.
[14]	严雅瑶, 顾敏, 刘秀梵. HA蛋白位点变异影响H7N9亚型流感病毒特性的研究进展[J]. 畜牧兽医学报, 2021, 52(8): 2093-2106.
[15]	蒋梅, 陈武, 翟俊琼, 卜婉迪, 谢逸伦, 刘灿彬, 单芬, 罗满林. 小熊猫源犬瘟热病毒株H、F基因的克隆及序列分析[J]. 畜牧兽医学报, 2021, 52(6): 1670-1676.